Pharmacokinetics of intravenous alendronate

Journal of Clinical Pharmacology

Volumn 39, Issue 4, 1999, Pages 385-393

  Cocquyt, Veronique ^b   Kline, Walter F ^a   Gertz, Barry J ^a   Van Belle, Simon J P ^b   Holland, Sherry D ^a   DeSmet, Marina ^b   Quan, Hui ^a   Vyas, Kamlesh P ^a   Zhang, Kanying E ^a   De Grève, Jacques ^b   Porras, Arturo G ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Merck Res Laboratories WP26 372 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG RETENTION; DRUG URINE LEVEL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PAGET BONE DISEASE; RADIOACTIVITY;

ADULT; AGED; ALENDRONATE; ANIMALS; AREA UNDER CURVE; CARBON RADIOISOTOPES; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEVER; HEADACHE; HUMANS; INFUSIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; POSTMENOPAUSE;

EID: 0032902283     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007958     Document Type: Article

References (19)

1. Cooper C: Bone mass throughout life: bone growth and involution. In, Francis RM (ed.): Osteoporosis, Pathogenesis and Management. Boston: Kluwer, 1990;1-26.
2. Fleisch H: Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcemic and metastatic bone disease. Drug 1991;42(6):919-944.
3. Chestnut CH III, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, Singer FR, Stock JL, Yood RA, Delmas PD, Kher U, Pryor-Tillotson S, Santora AC: Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-152.
4. Liberman UA, Stuart RW, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC, Lombardi A, Shah RV, Hirsch LJ, Karpf DB: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-1443.
5. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Pryor-Tillotson S, Reda C, Romanini L, Subrizi D, Wei L, Yates AJ: Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17(4):383-390.
6. Siris E, Weinstein RS, Altman R, Conte JM, Favus M, Lombardi A, Lyles K, McIlwain H, Murphy WA Jr, Reda C, Rude R, Seton M, Tiegs R, Thompson D, Tucci JR, Yates AJ, Zimering M: Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrine Metab 1996;81(3):961-967.
7. Lin JH, Duggan DE, Chen IW, Ellsworth RL: Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Disp 1991;19(5):926-932.
8. Lin JH, Chen IW, Duggan DE: Effect of dose, sex and age on the disposition of alendronate, a potent anti-osteolytic bisphosphonate, in rats. Drug Metab Dispos 1992;20:473-478.
9. Lin JH, Chen IW, DeLuna FA, Hichens M: Renal handling of alendronate in rats: an uncharacterized renal transport system. Drug Metab Dispos 1992;20:608-613.
10. Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H, Lasseter KC, Mucklow J, Porras AG: Studies of the oral bioavailability of alendronate. Clin Pharm Ther 1995;58(3):288-298.
11. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MNC, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG: Elimination and biochemical responses to alendronate in postmenopausal osteoporosis. J Bone Min Res 1997;12(10):1700-1707.
12. Kline WF, Matuszewski BK, Bayne WF: Improved determination of the bisphosphonate alendonate in human plasma and urine by automated precolumn derivatization and high performance liquid chromatography with fluorescence and electrochemical detection. J Chromatogr 1992;583:183-193.
13. Gibaldi M, Perrier D: Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982;409-416.
14. Francis MD, Martyodam RR: Chemical, biochemical and medicinal properties of the diphosphonates. In, Hilderbrand R L (ed.): The Role of Phosphonates in Living Systems. Boca Raton: C-R-C-Press-LLC;55-96.
15. Pentikainen PJ, Elomaa I, Nurmi A-K, Karkkainen S: Pharmacokinetics of clodronate in patients with metastatic breast cancer. Internat J Clin Pharmcol Ther Toxicol 1989;27(5):222-228.
16. 32P-EHDP in man. Calif Tissue Res 1977;22(Suppl.):428-429.
17. Leyvraz S, Hess U, Flesch G, Bauer J, Hauffe S, Ford JM, Burckhardt P: Pharmacokinetics of pamidronate in patients with bone metastases. JNCI 1992;84(10):788-792.
18. Conrad KA, Lee SM: Clodronate kinetics and dynamics. Clin Pharmacol Ther 1981;30(1):114-120.
19. Yakatan GJ, Pynor WJ, Talbert RL, Floyd BF, Slough CL, Ampulski RS, Benedict JJ: Clodronate kinetics and bioavailability. Clin Pharmacol Ther 1982;31(3):402-410.